(Bis)urea and (Bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators

Shiv K. Sharma, Yu Wu, Nora Steinbergs, Michael L. Crowley, Allison S. Hanson, Robert A. Casero, Patrick M. Woster

Research output: Contribution to journalArticlepeer-review


The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 overexpression is thought to contribute to the development of cancer. We recently reported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of isosteric ureas and thioureas that are also potent inhibitors of LSD1. These compounds induce increases in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2 and transcription factor GATA4. These compounds represent an important new series of epigenetic modulators with the potential for use as antitumor agents.

Original languageEnglish (US)
Pages (from-to)5197-5212
Number of pages16
JournalJournal of medicinal chemistry
Issue number14
StatePublished - Jul 22 2010

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of '(Bis)urea and (Bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators'. Together they form a unique fingerprint.

Cite this